Lowest-Rated Stocks NASDAQ:BLUE bluebird bio - BLUE Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding bluebird bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $4.32 -0.19 (-4.21%) (As of 03/28/2023 12:00 AM ET) Add Compare Share Share Today's Range$4.28▼$4.5050-Day Range$4.17▼$6.6952-Week Range$2.87▼$8.58Volume3.43 million shsAverage Volume3.91 million shsMarket Capitalization$358.21 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media bluebird bio MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside62.0% Upside$7.00 Price TargetShort InterestBearish24.73% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.40Based on 15 Articles This WeekInsider TradingSelling Shares$62,595 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.29) to ($2.67) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.94 out of 5 starsMedical Sector679th out of 1,002 stocksBiological Products, Except Diagnostic Industry112th out of 166 stocks 3.0 Analyst's Opinion Consensus Ratingbluebird bio has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 2 buy ratings, 6 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, bluebird bio has a forecasted upside of 62.0% from its current price of $4.32.Amount of Analyst Coveragebluebird bio has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted24.73% of the outstanding shares of bluebird bio have been sold short.Short Interest Ratio / Days to Coverbluebird bio has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in bluebird bio has recently increased by 12.20%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend Yieldbluebird bio does not currently pay a dividend.Dividend Growthbluebird bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLUE. Previous Next 2.4 News and Social Media Coverage News Sentimentbluebird bio has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for bluebird bio this week, compared to 4 articles on an average week.Search Interest22 people have searched for BLUE on MarketBeat in the last 30 days. This is an increase of 22% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added bluebird bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -22% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, bluebird bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $62,595.00 in company stock.Percentage Held by InsidersOnly 2.20% of the stock of bluebird bio is held by insiders.Percentage Held by Institutions79.01% of the stock of bluebird bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for bluebird bio are expected to grow in the coming year, from ($4.29) to ($2.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of bluebird bio is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of bluebird bio is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratiobluebird bio has a P/B Ratio of 0.81. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About bluebird bio (NASDAQ:BLUE) Stockbluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.Read More Receive BLUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter. Email Address BLUE Stock News HeadlinesMarch 28, 2023 | msn.combluebird bio Earnings PreviewMarch 28, 2023 | markets.businessinsider.combluebird bio earnings preview: what Wall Street is expectingMarch 28, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …March 27, 2023 | marketwatch.comAlpha Thalassemia Market Share and Forecast till 2030March 27, 2023 | americanbankingnews.combluebird bio (BLUE) Scheduled to Post Earnings on WednesdayMarch 24, 2023 | marketwatch.comCAR T-Cell Therapy Market 2023 Size and Forecast to 2030March 23, 2023 | marketwatch.comAcquired Aplastic Anemia Market Size 2023 Global Industry Development by Future Demand and Forecast till 2026March 22, 2023 | msn.comBuyer Beware: 3 Risks to Watch for With Biotech Stocks in 2023March 28, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …March 19, 2023 | americanbankingnews.comStockNews.com Begins Coverage on bluebird bio (NASDAQ:BLUE)March 18, 2023 | marketwatch.comSickle Cell Disease Treatment Market by Product Type-2029March 18, 2023 | americanbankingnews.combluebird bio, Inc. (NASDAQ:BLUE) Receives $7.00 Consensus Price Target from AnalystsMarch 16, 2023 | marketwatch.comGlobal Advanced Therapy Medicinal Products Market | New Investment Opportunities and Future Outlook 2023-2028March 14, 2023 | marketwatch.comHow and Where the Advanced Therapy Medicinal Products Market is Set to Grow in forecast period 2029March 14, 2023 | marketwatch.comHow and Where the Sickle-cell Anemia Therapeutics Market 2023 is Set to Grow in forecast period 2028March 12, 2023 | nasdaq.comState Street Now Owns 11.03% of bluebird bio (BLUE)March 7, 2023 | marketwatch.comThe Rise of Sickle Cell Anemia Therapeutics Market 2023 and Its Impact on the Global Industry till 2028March 7, 2023 | cnbc.comShares of this under-the-radar cell therapy stock are set to double, says BairdMarch 7, 2023 | markets.businessinsider.comAnalyst Expectations for bluebird bio's FutureFebruary 24, 2023 | marketwatch.comCAR T-Cell Therapy Market Size 2023 Is Projected to Rise at a Positive CAGR by Forecast to 2028February 22, 2023 | marketwatch.comCAR T-Cell Therapy Market Size Global Research Report, 2023 - 2028February 18, 2023 | marketwatch.comCAR T-Cell Therapy Market Size 2023 Is Expected To Witness Huge Demand With Future Growth by 2028February 10, 2023 | thestreet.comBlood Disorder Patients Respond Strongly to Bluebird Bio Gene TherapyFebruary 8, 2023 | marketwatch.comAdrenoleukodystrophy Drugs Market 2023 In-Depth Analysis by Focusing on Leading Key Players: Bluebird Bio Inc, NeuroVia, Inc., OrpherisFebruary 8, 2023 | finance.yahoo.com1 Beaten-Down Stock That Has a Lot to Prove in 2023February 3, 2023 | finance.yahoo.comHere's why 2seventy bio's chief executive thinks 2023 will be a 'special year'January 30, 2023 | finance.yahoo.combluebird bio, Inc. (NASDAQ:BLUE) is favoured by institutional owners who hold 58% of the companySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BLUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter. Email Address BLUE Company Calendar Last Earnings11/05/2021Today3/28/2023Next Earnings (Confirmed)3/29/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BLUE CUSIPN/A CIK1293971 Webwww.bluebirdbio.com Phone(339) 499-9300FaxN/AEmployees518Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.00 High Stock Price Forecast$10.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+62.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($6.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-819,380,000.00 Net Margins-8,828.28% Pretax Margin-8,384.38% Return on Equity-173.58% Return on Assets-77.81% Debt Debt-to-Equity RatioN/A Current Ratio1.27 Quick Ratio1.27 Sales & Book Value Annual Sales$3.66 million Price / Sales97.87 Cash FlowN/A Price / Cash FlowN/A Book Value$5.34 per share Price / Book0.81Miscellaneous Outstanding Shares82,920,000Free Float81,099,000Market Cap$358.21 million OptionableOptionable Beta0.95 Key ExecutivesAndrew ObenshainPresident, Chief Executive Officer & DirectorThomas J. KlimaChief Operating & Commercial OfficerChristopher Stanley KrawtschukTreasurer, Chief Financial & Accounting OfficerRichard ColvinChief Medical OfficerMelissa BonnerSenior Vice President-ResearchKey CompetitorsAmbrx BiopharmaNYSE:AMAMOmega TherapeuticsNASDAQ:OMGAMonte Rosa TherapeuticsNASDAQ:GLUEAura BiosciencesNASDAQ:AURAVigil NeuroscienceNASDAQ:VIGLView All CompetitorsInsiders & InstitutionsMetLife Investment Management LLCBought 5,607 shares on 3/23/2023Ownership: 0.053%Alliancebernstein L.P.Sold 20,800 shares on 2/16/2023Ownership: 0.121%Point72 Middle East FZEBought 44,092 shares on 2/16/2023Ownership: 0.053%Financial Advocates Investment ManagementSold 30,381 shares on 2/16/2023Ownership: 0.018%Mariner LLCBought 2,043 shares on 2/15/2023Ownership: 0.022%View All Insider TransactionsView All Institutional Transactions BLUE Stock - Frequently Asked Questions Should I buy or sell bluebird bio stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last twelve months. There are currently 2 sell ratings, 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BLUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares. View BLUE analyst ratings or view top-rated stocks. What is bluebird bio's stock price forecast for 2023? 10 Wall Street analysts have issued twelve-month price targets for bluebird bio's stock. Their BLUE share price forecasts range from $3.00 to $10.00. On average, they anticipate the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 62.0% from the stock's current price. View analysts price targets for BLUE or view top-rated stocks among Wall Street analysts. How have BLUE shares performed in 2023? bluebird bio's stock was trading at $6.92 at the beginning of the year. Since then, BLUE stock has decreased by 37.6% and is now trading at $4.32. View the best growth stocks for 2023 here. Are investors shorting bluebird bio? bluebird bio saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 20,510,000 shares, an increase of 12.2% from the February 28th total of 18,280,000 shares. Based on an average daily volume of 3,780,000 shares, the short-interest ratio is presently 5.4 days. View bluebird bio's Short Interest. When is bluebird bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023. View our BLUE earnings forecast. How were bluebird bio's earnings last quarter? bluebird bio, Inc. (NASDAQ:BLUE) released its quarterly earnings data on Friday, November, 5th. The biotechnology company reported ($3.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.65) by $0.51. The biotechnology company earned $22.70 million during the quarter, compared to analysts' expectations of $39.07 million. bluebird bio had a negative trailing twelve-month return on equity of 173.58% and a negative net margin of 8,828.28%. bluebird bio's quarterly revenue was up 17.6% on a year-over-year basis. During the same period in the previous year, the business earned ($2.94) EPS. What ETFs hold bluebird bio's stock? ETFs with the largest weight of bluebird bio (NASDAQ:BLUE) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Products ETF (BBP), Invesco DWA Healthcare Momentum ETF (PTH), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Global X Genomics & Biotechnology ETF (GNOM), Invesco Nasdaq Future Gen 200 ETF (QQQS) and Invesco DWA SmallCap Momentum ETF (DWAS). What is Nick Leschly's approval rating as bluebird bio's CEO? 91 employees have rated bluebird bio Chief Executive Officer Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among the company's employees. What other stocks do shareholders of bluebird bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN). What is bluebird bio's stock symbol? bluebird bio trades on the NASDAQ under the ticker symbol "BLUE." Who are bluebird bio's major shareholders? bluebird bio's stock is owned by a variety of institutional and retail investors. Top institutional investors include Tang Capital Management LLC (5.59%), Dimensional Fund Advisors LP (2.44%), Credit Suisse AG (2.00%), Geode Capital Management LLC (1.97%), JPMorgan Chase & Co. (1.56%) and Point72 Asset Management L.P. (1.46%). Insiders that own company stock include Alison Cecily Finger, Andrew Obenshain, Anne-Virginie Eggimann, David Davidson, Jason Cole, Jessica Whitten, Joanne Smith-Farrell, Katy Burnett, Kory James Wentworth, Nick Leschly, Richard A Colvin, Thomas J Klima and William D Baird III. View institutional ownership trends. How do I buy shares of bluebird bio? Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is bluebird bio's stock price today? One share of BLUE stock can currently be purchased for approximately $4.32. How much money does bluebird bio make? bluebird bio (NASDAQ:BLUE) has a market capitalization of $358.21 million and generates $3.66 million in revenue each year. The biotechnology company earns $-819,380,000.00 in net income (profit) each year or ($6.10) on an earnings per share basis. How many employees does bluebird bio have? The company employs 518 workers across the globe. How can I contact bluebird bio? bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.bluebirdbio.com. The biotechnology company can be reached via phone at (339) 499-9300 or via email at investor@bluebirdbio.com. This page (NASDAQ:BLUE) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.